CCC
MRK icon

Crescent Capital Consulting’s Merck MRK Stock Holding History

Crescent Capital Consulting’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$40K Buy
+5
New +$398 0.01% 307

Other funds holding MRK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Crescent Capital Consulting's MRK Position: Q4 2021 in Review

Crescent Capital Consulting increased its Merck (MRK) stake by 8.6% in Q4 2021, buying an estimated $287K and bringing the position to 45,285 shares worth $3.47M. The position accounts for 0.57% of the portfolio, ranked #38.

Crescent Capital Consulting first reported a position in MRK in Q4 2020 and has held it in 5 quarters since. The position peaked at $3.54M in Q4 2020. 2,902 funds tracked by Wall St. Rank hold MRK as of Q4 2021.

  • Crescent Capital Consulting held 45,285 shares of Merck worth $3.47M as of Q4 2021.
  • Crescent Capital Consulting bought 3,600 Merck shares in Q4 2021, an estimated $287K.
  • Merck made up 0.57% of Crescent Capital Consulting's portfolio in Q4 2021, its #38 holding.
  • Crescent Capital Consulting first reported a position in Merck in Q4 2020 and has held it in 5 quarters since.
  • Crescent Capital Consulting's Merck position peaked at $3.54M in Q4 2020.
  • 2,902 funds tracked by Wall St. Rank held Merck as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.